AI assistant
Evotec SE — Regulatory Filings 2013
Jul 8, 2013
151_rns_2013-07-08_c11035d2-77a5-4339-82b2-d9b74be999cc.html
Regulatory Filings
Open in viewerOpens in your device viewer
News Details
Ad-hoc | 8 July 2013 13:26
Evotec AG: Evotec to realign Discovery Chemistry Operations
Evotec AG / Key word(s): Strategic Company Decision
08.07.2013 13:26
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
08 July 2013
Ad hoc release according to § 15 WpHG
Evotec to realign Discovery Chemistry Operations
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard,
ISIN: DE 000 566480 9, WKN 566480) today announced that it will close its
Chemistry Operations in Thane, India. All chemistry efforts will now be
performed at its Abingdon (UK) facility. All project work in Thane will be
finished at the end of September and Evotec (India) Private Ltd will be
wound down from then.
As a consequence 120 people will have to leave the company and Evotec will
take a one-time impairment charge of up to EUR 4 m in Q3 2013. At the same
time Evotec confirms its revenue, profitability and cash guidance for 2013.
Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Manfred
Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560
81-242, [email protected]
08.07.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service